Renal Safety of Zoledronic Acid in Patients with Breast Cancer
Zoledronic acid was found to have a renal safety profile comparable to that of pamidronate in patients with breast cancer. No patient with breast cancer treated with zoledronic acid was found to have experienced a NCI Common Toxicity Criteria of grade 3 or 4 serum creatinine increase.
To view the full article please click here.
Dates
Posted On: 7 November, 2005
Modified On: 20 March, 2014
Tags
Created by:

Login













